Information Provided By: 
Fly News Breaks for May 15, 2018
GALT
May 15, 2018 | 07:23 EDT
H.C. Wainwright analyst Ed Arce raised his price target for Galectin Therapeutics to $12 after the company said it is proceeding with plans for a Phase 3 clinical trial program with galectin-3 inhibitor GR-MD-02 in NASH cirrhosis, following a meeting with the FDA earlier this month. Yesterday's announcement is the most meaningful stock catalyst since the top-line results of the Phase 2b NASH-CX trial in early December 2017, Arce tells investors in a research note. The analyst keeps a Buy rating on Galectin.
News For GALT From the Last 2 Days
There are no results for your query GALT
